C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
20 Junho 2023 - 8:00AM
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage
biopharmaceutical company dedicated to advancing targeted protein
degradation science to develop a new generation of small-molecule
medicines and transform how disease is treated, today announced the
appointment of Leonard (Len) Reyno, M.D., as chief medical officer,
effective July 10, 2023. Dr. Reyno is a seasoned biotech
executive with nearly 30 years of clinical development
experience, spanning first-in-human studies to Phase IV clinical
trials. At C4T, Dr. Reyno will be responsible for driving C4T’s
clinical strategy to advance its promising pipeline of degrader
therapies.
“We look forward to leveraging Len’s track record of advancing
novel oncology therapeutics to patients, deep strategic and
operational experience in clinical development and organizational
leadership capabilities,” said Andrew Hirsch, president and chief
executive officer of C4 Therapeutics. “I am excited to work closely
with Len, who will play a critical role in leading our clinical
development organization, shaping the development strategy of our
clinical-stage degrader programs and collaborating with our
discovery organization as we advance our preclinical portfolio of
targeted protein degradation therapies.”
Dr. Reyno joins C4T from Pionyr Immunotherapeutics, where he
most recently served as president, research & development and
chief medical officer and led the company to advancing two novel
therapeutics into the clinic. Prior to Pionyr, he was executive
vice president and chief medical officer at ORIC Pharmaceuticals,
leading their first product candidate into human trials. Before
that, he served in various medical leadership roles at Agensys, a
subsidiary of Astellas Pharma, over the course of a decade; there,
he led clinical-stage development of multiple antibody products to
novel targets through clinical proof of concept, including the
early clinical development of Padcev® for bladder cancer. Earlier
in his career, at Genentech and Aventis, Dr. Reyno led FDA approval
teams for Herceptin® for HER2+ breast cancer and Taxotere® for the
adjuvant treatment of breast cancer, respectively. Prior to joining
industry, Dr. Reyno was an academic oncologist at Queen Elizabeth
II Health Sciences Centre in Nova Scotia, Canada, and previously at
McMaster University where he gained extensive experience as a
clinician as well as serving as a principal investigator on
multiple trials with the National Cancer Institute of
Canada. Dr. Reyno earned a B.Sc. in chemistry at Dalhousie
University and an M.D. from McMaster University Medical
School.
“C4T’s differentiated approach to targeted protein degradation
science, compelling multi-asset clinical portfolio and rich
preclinical pipeline of novel oncology targets, attracted me to the
role,” said Dr. Reyno. “I am looking forward to working with the
C4T leadership team and applying my clinical development experience
across all phases of drug development to create a new generation of
medicines that have the potential to transform patients’
lives.”
About C4 TherapeuticsC4 Therapeutics (C4T)
(Nasdaq: CCCC) is a clinical-stage biopharmaceutical company
dedicated to delivering on the promise of targeted protein
degradation science to create a new generation of medicines that
transforms patients’ lives. C4T is leveraging its
TORPEDO® platform to efficiently design and optimize
small-molecule medicines that harness the body’s natural protein
recycling system to rapidly degrade disease-causing proteins,
offering the potential to overcome drug resistance, drug
undruggable targets and improve patient outcomes. C4T is advancing
multiple targeted oncology programs to the clinic and expanding its
research platform to deliver the next wave of medicines for
difficult-to-treat diseases. For more information, please
visit www.c4therapeutics.com.
Forward-Looking StatementsThis press release
contains “forward-looking statements” of C4 Therapeutics, Inc.
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements may include, but may not
be limited to, express or implied statements regarding our ability
to develop potential therapies for patients; the design and
potential efficacy of our therapeutic approaches; the predictive
capability of our TORPEDO® platform in the development of
novel, selective, orally bioavailable BiDAC™ and MonoDAC™
degraders; the potential timing, design and advancement of our
preclinical studies and clinical trials, including the potential
timing for and receipt of regulatory authorization related to
clinical trials and other clinical development activities including
clinical trial commencement; our ability and the potential to
successfully manufacture and supply our product candidates for
clinical trials; our ability to replicate results achieved in our
preclinical studies or clinical trials in any future studies or
trials; regulatory developments in the United States and foreign
countries; and our ability to fund our future operations. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs of future events and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to: uncertainties
related to the initiation, timing, advancement and conduct of
preclinical and clinical studies and other development requirements
for our product candidates; the risk that any one or more of our
product candidates will cost more to develop or may not be
successfully developed and commercialized; and the risk that the
results of preclinical studies and/or clinical trials will or will
not be predictive of results in connection with future studies or
trials. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or
Quarterly Report on Form 10-Q, as filed with the Securities and
Exchange Commission. All information in this press release is as of
the date of the release, and C4 Therapeutics undertakes no duty to
update this information unless required by law.
Investor Contact: Courtney SolbergSenior
Manager, Investor RelationsCSolberg@c4therapeutics.com
Media Contact: Loraine
Spreen Director, Corporate Communications & Patient
Advocacy LSpreen@c4therapeutics.com
C4 Therapeutics (NASDAQ:CCCC)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
C4 Therapeutics (NASDAQ:CCCC)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024